AI-generated summary
The authors report a randomized trial of 74 people with congenital color vision deficiency, comparing four weeks of twice-daily virtual reality goggle video with red and green alternating images against a no-treatment control group. They report improved scores on several color tests in the treatment group and reduced FM-100 error scores, with the authors concluding the approach may hold promise as a potential treatment option.
- Participants
- 74
- Who or what was studied
- People with congenital color vision deficiency
- Limits stated in the abstract
- The authors describe this as a preliminary trial, and the abstract does not report how the control group was blinded or how long-term effects were assessed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Purpose
This study presents a novel randomized controlled trial investigating photobiomodulation (PBM) therapy as an intervention method for color vision deficiency (CVD).
Methods
A total of 74 participants with CVD were assigned to either the PBM group or the control group. In the PBM group, participants wore virtual reality (VR) goggles twice daily, with a 12-h interval, over a four-week period. The VR video consisted of alternating red and green images, each presented for 5 s, totaling 6 min and 20 s. No treatment was administered to the control group. Color vision improvement was assessed using Yu's, Ishihara's pseudoachromatic plates, Color Blindness Check (CBC), and FM-100 Hue total error score (TES).
Results
After 4 weeks, in terms of Yu's and Ishihara's Plates, the patients in PBM group could identify increasing pieces (before: 1.6 ± 1.6, 2.3 ± 2.2; 4 weeks: 6.5 ± 4.4, 5.4 ± 2.9), while in control group, the number was before: 2.6 ± 3.4, 2.6 ± 2.5; 4 weeks: 3.3 ± 3.6, 2.9 ± 2.2. As for CBC scores, the patients in PBM also showed improved high scores (before: 2353.3 ± 700.0; 4 weeks: 2693.6 ± 642.5). Moreover, PBM treatment resulted in a significant reduction of FM-100 scores (before: 298.0 ± 211.3; 4 weeks: 202.1 ± 114.4).
Conclusion
These findings suggest that PBM therapy holds promise as a potential treatment option for individuals with CVD. CLINICAL
Trial Registration
The study received approval from the Ethics Committee of PLA General Hospital, China (KY2021-017). Additionally, it was registered as a Chinese domestic clinical trial (ChiCTR2200056761) at "http://Chictr.org.cn/index.aspx".
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Control group, Randomized controlled trial, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.